We recently spoke with Daniel Berman, Global Health Lead at Nesta Challenges, to learn about the Longitude Prize, a £10 million prize fund with an £8 million pay-out, which will be awarded to a team that invents an affordable, accurate, fast and easy-to-use test for bacterial infections.Read More
Companion diagnostics (CDx), i.e. in vitro medical devices, and next-generation sequencing (NGS), are both essential to the practice of precision medicine. As new regulations are introduced, pharma companies and manufacturers alike need to ensure their CDx processes are compliant or we could see a deceleration in the flow of new precision therapies in the near future.Read More
Agilent are working to increase the utility of NGS in the diagnostics field and in personalized medicine. We recently spoke with Ronda Allen, Head of R&D at Agilent, to learn more about two of Agilent's newest products in this space, the Cancer All-in-one (AIO) panels, and the Magnis NGS Library Prep System.Read More
Technology Networks recently spoke with Rosengarten and Raymond Mercier, VP and GM, Molecular Biology, Thermo Fisher Scientific, to learn more about how the co-marketing agreement between Thermo Fisher Scientific and Genialis will help ease the burden of the "informatics bottleneck" for research scientists.Read More
A recent collaborative study between Examen and the Lister Fertility Clinic in London used Examen’s COMET assay to measure sperm DNA damage in men with unexplained infertility. We spoke with Professor Sheena Lewis, CEO of Examen, to learn more about the study, the links between sperm DNA damage and infertility, and the value of adding this parameter to fertility testing.Read More
Megatrends are overarching trends, ones that seed and embrace multiple market and technology developments. These trends already exist in our world today but are going to be even more important in the years to come. Here we highlight three technology megatrends that could be highly significant to our future.Read More
A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.
Predicting the reprogramming factors necessary to induce cell conversion has largely relied on trial and error, revealing the need for a more systematic approach. To learn about Mogrify's approach to achieving cell conversion through transdifferentiation, we interviewed Pierre-Louis Joffrin, Corporate Development Executive at Mogrify.Read More